Cargando…

Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren’s syndrome: a literature review

Lung involvement in systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome (pSS) has extensively been outlined with a multiplicity of different manifestations. In SLE, the most frequent finding is pleural effusion, while in pSS, airway disease and parenchymal disorders prevail. In both ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Depascale, Roberto, Del Frate, Giulia, Gasparotto, Michela, Manfrè, Valeria, Gatto, Mariele, Iaccarino, Luca, Quartuccio, Luca, De Vita, Salvatore, Doria, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Interstitial Lung Disease in Autoimmune Rheumatic Disorders
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488521/ https://www.ncbi.nlm.nih.gov/pubmed/34616495 http://dx.doi.org/10.1177/1759720X211040696

Ejemplares similares

Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review
por: Campochiaro, Corrado, et al.
Publicado: (2022)

Natural history and screening of interstitial lung disease in systemic autoimmune rheumatic disorders
por: Panagopoulos, Panagiotis, et al.
Publicado: (2021)

Biomarkers for interstitial lung disease and acute-onset diffuse interstitial lung disease in rheumatoid arthritis
por: Furukawa, Hiroshi, et al.
Publicado: (2021)

Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders
por: Kuwana, Masataka, et al.
Publicado: (2021)

Autologous stem-cell transplantation in systemic sclerosis-associated interstitial lung disease: early action in selected patients rather than escalation therapy for all
por: Spierings, J., et al.
Publicado: (2021)

The role of antifibrotic therapies in the treatment of systemic sclerosis–associated interstitial lung disease
por: Boleto, Gonçalo, et al.
Publicado: (2022)

The role of antifibrotics in the treatment of rheumatoid arthritis–associated interstitial lung disease
por: Liang, Minrui, et al.
Publicado: (2022)

Interstitial lung disease pathology in systemic sclerosis
por: Konopka, Kristine E., et al.
Publicado: (2021)

Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease
por: Wilfong, Erin M., et al.
Publicado: (2021)

Systemic sclerosis associated interstitial lung disease: a survey of current practices in France
por: Nicolas, Amélie, et al.
Publicado: (2023)

Rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren’s syndrome shared megakaryocyte expansion in peripheral blood
por: Wang, Yukai, et al.
Publicado: (2022)

Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials
por: Lancaster, Lisa, et al.
Publicado: (2019)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial
por: Popmihajlov, Zoran, et al.
Publicado: (2022)

Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy
por: Sgalla, Giacomo, et al.
Publicado: (2015)

Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease
por: Flaherty, Kevin R, et al.
Publicado: (2017)

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)
por: Maher, Toby M, et al.
Publicado: (2023)

Development of a Conceptual Model to Understand Disease Burden in Patients With Systemic Lupus Erythematosus and Organ Damage
por: Broderick, Lynne, et al.
Publicado: (2023)

Disease criteria of systemic lupus erythematosus (SLE); the potential role of non-criteria autoantibodies
por: Irure-Ventura, Juan, et al.
Publicado: (2022)

Defining the pathway to timely diagnosis and treatment of interstitial lung disease: a US Delphi survey
por: Case, Amy Hajari, et al.
Publicado: (2023)

Diagnostic markers and potential therapeutic agents for Sjögren’s syndrome screened through multiple machine learning and molecular docking
por: Zhou, Liqing, et al.
Publicado: (2023)

Association between Toxoplasma gondii and systemic lupus erythematosus: A systematic review and meta-analysis
por: Bassett, Pierce, et al.
Publicado: (2022)

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials
por: Saketkoo, Lesley Ann, et al.
Publicado: (2014)

Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosis
por: McGrath, Emmet E, et al.
Publicado: (2012)

A qualitative study of informal caregivers’ perspectives on the effects of idiopathic pulmonary fibrosis
por: Belkin, Amanda, et al.
Publicado: (2014)

Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry
por: Behr, Juergen, et al.
Publicado: (2014)

Cross-Atlantic modification and validation of the A Tool to Assess Quality of Life in Idiopathic Pulmonary Fibrosis (ATAQ-IPF-cA)
por: Yorke, Janelle, et al.
Publicado: (2014)

Combined pulmonary fibrosis and emphysema: effect of pulmonary rehabilitation in comparison with chronic obstructive pulmonary disease
por: Tomioka, Hiromi, et al.
Publicado: (2016)

Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
por: Lancaster, Lisa, et al.
Publicado: (2016)

Rationale for and design of the Idiopathic Pulmonary Fibrosis–PRospective Outcomes (IPF-PRO) registry
por: O'Brien, Emily C, et al.
Publicado: (2016)

Sequencing of idiopathic pulmonary fibrosis-related genes reveals independent single gene associations
por: Coghlan, Meghan A, et al.
Publicado: (2014)

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
por: Nathan, Steven D, et al.
Publicado: (2016)

Antineutrophil cytoplasmic antibody-positive conversion and microscopic polyangiitis development in patients with idiopathic pulmonary fibrosis
por: Kagiyama, Naho, et al.
Publicado: (2015)

Lymphangiogenic factors are associated with the severity of hypersensitivity pneumonitis
por: Yamashita, Masahiro, et al.
Publicado: (2015)

Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
por: Kreuter, Michael, et al.
Publicado: (2017)

Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF
por: Mercer, Paul F, et al.
Publicado: (2016)

Yield of EBUS-TBNA for the diagnosis of sarcoidosis: impact of operator and cytopathologist experience
por: Navasakulpong, Asma, et al.
Publicado: (2016)

Randomised clinical trial of an early palliative care intervention (SUPPORT) for patients with idiopathic pulmonary fibrosis (IPF) and their caregivers: protocol and key design considerations
por: Lindell, Kathleen Oare, et al.
Publicado: (2018)

Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials
por: Nathan, Steven D, et al.
Publicado: (2018)

Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK®trial
por: Maher, Toby M, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_13v9elukb1bsgn3fgi0rlqnah2